Skip to content
2000
image of Genetic Uncertainties Fueling Cholangiocarcinoma Progression

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive type of liver cancer that is difficult to treat due to its complicated causes. It is typically detected in advanced stages, leaving patients with few treatment options. Recent breakthroughs in genomic research have emphasized the pivotal significance of genetic changes in the initiation and advancement of intrahepatic cholangiocarcinoma (iCCA). The objective of this study was to investigate the genetic relationships that are responsible for the development and advancement of intrahepatic cholangiocarcinoma (iCCA), with a specific focus on crucial mutations, gene expressions, and molecular pathways that contribute to the formation of tumors. By performing a thorough examination of the genome, we have discovered multiple genetic abnormalities that are frequently linked to intrahepatic cholangiocarcinoma (iCCA), such as changes in the , and genes. These mutations have been discovered to promote cancer-causing processes by interfering with regular cellular functioning and increasing the likelihood of malignant transformation. Furthermore, the study has examined the influence of epigenetic alterations on gene expression, which enhances the diversity and aggressive characteristics of iCCA. The results have emphasized the significance of genetic profiling in comprehending the molecular pathways that underlie intrahepatic cholangiocarcinoma (iCCA) and highlighting prospective targets for therapy. This review has made an attempt to provide a clear understanding of the genetic characteristics of iCCA, which can lead to the development of tailored treatment strategies. This has the potential to improve outcomes for patients with this challenging condition.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cg/10.2174/0113892029392506251115053421
2026-02-24
2026-03-02

  • From This Site

    /content/journals/cg/10.2174/0113892029392506251115053421
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sia D. Losic B. Moeini A. Cabellos L. Hao K. Revill K. Bonal D. Miltiadous O. Zhang Z. Hoshida Y. Cornella H. Castillo-Martin M. Pinyol R. Kasai Y. Roayaie S. Thung S.N. Fuster J. Schwartz M.E. Waxman S. Cordon-Cardo C. Schadt E. Mazzaferro V. Llovet J.M. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 2015 6 1 6087 10.1038/ncomms7087 25608663
    [Google Scholar]
  2. Farshidfar F. Zheng S. Gingras M.C. Newton Y. Shih J. Robertson A.G. Hinoue T. Hoadley K.A. Gibb E.A. Roszik J. Covington K.R. Wu C.C. Shinbrot E. Stransky N. Hegde A. Yang J.D. Reznik E. Sadeghi S. Pedamallu C.S. Ojesina A.I. Hess J.M. Auman J.T. Rhie S.K. Bowlby R. Borad M.J. Zhu A.X. Stuart J.M. Sander C. Akbani R. Cherniack A.D. Deshpande V. Mounajjed T. Foo W.C. Torbenson M.S. Kleiner D.E. Laird P.W. Wheeler D.A. McRee A.J. Bathe O.F. Andersen J.B. Bardeesy N. Roberts L.R. Kwong L.N. Akbani R. Allotey L.K. Ally A. Alvaro D. Andersen J.B. Appelbaum E.L. Arora A. Auman J.T. Balasundaram M. Balu S. Bardeesy N. Bathe O.F. Baylin S.B. Beroukhim R. Berrios M. Bodenheimer T. Boice L. Bootwalla M.S. Borad M.J. Bowen J. Bowlby R. Bragazzi M.C. Brooks D. Cardinale V. Carlsen R. Carpino G. Carvalho A.L. Chaiteerakij R. Chandan V.C. Cherniack A.D. Chin L. Cho J. Choe G. Chuah E. Chudamani S. Cibulskis C. Cordes M.G. Covington K.R. Crain D. Curley E. De Rose A.M. Defreitas T. Demchok J.A. Deshpande V. Dhalla N. Ding L. Evason K. Farshidfar F. Felau I. Ferguson M.L. Foo W.C. Franchitto A. Frazer S. Fronick C.C. Fulton L.A. Fulton R.S. Gabriel S.B. Gardner J. Gastier-Foster J.M. Gaudio E. Gehlenborg N. Genovese G. Gerken M. Getz G. Giama N.H. Gibbs R.A. Gingras M-C. Giuliante F. Grazi G.L. Hayes D.N. Hegde A.M. Heiman D.I. Hess J.M. Hinoue T. Hoadley K.A. Holbrook A. Holt R.A. Hoyle A.P. Huang M. Hutter C.M. Jefferys S.R. Jones S.J.M. Jones C.D. Kasaian K. Kelley R.K. Kim J. Kleiner D.E. Kocher J-P.A. Kwong L.N. Lai P.H. Laird P.W. Lawrence M.S. Leraas K.M. Lichtenberg T.M. Lin P. Liu W. Liu J. Lolla L. Lu Y. Ma Y. Mallery D. Mardis E.R. Marra M.A. Matsushita M.M. Mayo M. McLellan M.D. McRee A.J. Meier S. Meng S. Meyerson M. Mieczkowski P.A. Miller C.A. Mills G.B. Moore R.A. Morris S. Mose L.E. Moser C.D. Mounajjed T. Mungall A.J. Mungall K. Murray B.A. Naresh R. Newton Y. Noble M.S. O’Brien D.R. Ojesina A.I. Parker J.S. Patel T.C. Paulauskis J. Pedamallu C.S. Penny R. Perou C.M. Perou A.H. Pihl T. Radenbaugh A.J. Ramirez N.C. Rathmell W.K. Reznik E. Rhie S.K. Roach J. Roberts L.R. Robertson A.G. Sadeghi S. Saksena G. Sander C. Schein J.E. Schmidt H.K. Schumacher S.E. Shelton C. Shelton T. Shen R. Sheth M. Shi Y. Shih J. Shinbrot E. Shroff R. Simons J.V. Sipahimalani P. Skelly T. Sofia H.J. Soloway M.G. Stoppler H. Stransky N. Stuart J. Sun Q. Tam A. Tan D. Tarnuzzer R. Thiessen N. Thorne L.B. Torbenson M.S. Van Den Berg D.J. Veluvolu U. Verhaak R.G.W. Voet D. Wan Y. Wang Z. Weinstein J.N. Weisenberger D.J. Wheeler D.A. Wilson R.K. Wise L. Wong T. Wu C-C. Wu Y. Xi L. Yang J.D. Yang L. Zenklusen J.C. Zhang H. Zhang J.J. Zheng S. Zmuda E. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017 18 11 2780 2794 10.1016/j.celrep.2017.02.033 28297679
    [Google Scholar]
  3. Ross J.S. Wang K. Gay L. Al-Rohil R. Rand J.V. Jones D.M. Lee H.J. Sheehan C.E. Otto G.A. Palmer G. Yelensky R. Lipson D. Morosini D. Hawryluk M. Catenacci D.V.T. Miller V.A. Churi C. Ali S. Stephens P.J. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014 19 3 235 242 10.1634/theoncologist.2013‑0352 24563076
    [Google Scholar]
  4. Chan-on W. Nairismägi M.L. Ong C.K. Lim W.K. Dima S. Pairojkul C. Lim K.H. McPherson J.R. Cutcutache I. Heng H.L. Ooi L. Chung A. Chow P. Cheow P.C. Lee S.Y. Choo S.P. Tan I.B.H. Duda D. Nastase A. Myint S.S. Wong B.H. Gan A. Rajasegaran V. Ng C.C.Y. Nagarajan S. Jusakul A. Zhang S. Vohra P. Yu W. Huang D. Sithithaworn P. Yongvanit P. Wongkham S. Khuntikeo N. Bhudhisawasdi V. Popescu I. Rozen S.G. Tan P. Teh B.T. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers. Nat. Genet. 2013 45 12 1474 1478 10.1038/ng.2806 24185513
    [Google Scholar]
  5. Jiao Y. Pawlik T.M. Anders R.A. Selaru F.M. Streppel M.M. Lucas D.J. Niknafs N. Guthrie V.B. Maitra A. Argani P. Offerhaus G.J.A. Roa J.C. Roberts L.R. Gores G.J. Popescu I. Alexandrescu S.T. Dima S. Fassan M. Simbolo M. Mafficini A. Capelli P. Lawlor R.T. Ruzzenente A. Guglielmi A. Tortora G. de Braud F. Scarpa A. Jarnagin W. Klimstra D. Karchin R. Velculescu V.E. Hruban R.H. Vogelstein B. Kinzler K.W. Papadopoulos N. Wood L.D. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 2013 45 12 1470 1473 10.1038/ng.2813 24185509
    [Google Scholar]
  6. Nakamura H. Arai Y. Totoki Y. Shirota T. Elzawahry A. Kato M. Hama N. Hosoda F. Urushidate T. Ohashi S. Hiraoka N. Ojima H. Shimada K. Okusaka T. Kosuge T. Miyagawa S. Shibata T. Genomic spectra of biliary tract cancer. Nat. Genet. 2015 47 9 1003 1010 10.1038/ng.3375 26258846
    [Google Scholar]
  7. Saha S.K. Parachoniak C.A. Ghanta K.S. Fitamant J. Ross K.N. Najem M.S. Gurumurthy S. Akbay E.A. Sia D. Cornella H. Miltiadous O. Walesky C. Deshpande V. Zhu A.X. Hezel A.F. Yen K.E. Straley K.S. Travins J. Popovici-Muller J. Gliser C. Ferrone C.R. Apte U. Llovet J.M. Wong K.K. Ramaswamy S. Bardeesy N. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2014 513 7516 110 114 10.1038/nature13441 25043045
    [Google Scholar]
  8. Borger D.R. Tanabe K.K. Fan K.C. Lopez H.U. Fantin V.R. Straley K.S. Schenkein D.P. Hezel A.F. Ancukiewicz M. Liebman H.M. Kwak E.L. Clark J.W. Ryan D.P. Deshpande V. Dias-Santagata D. Ellisen L.W. Zhu A.X. Iafrate A.J. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012 17 1 72 79 10.1634/theoncologist.2011‑0386 22180306
    [Google Scholar]
  9. Arai Y. Totoki Y. Hosoda F. Shirota T. Hama N. Nakamura H. Ojima H. Furuta K. Shimada K. Okusaka T. Kosuge T. Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014 59 4 1427 1434 10.1002/hep.26890 24122810
    [Google Scholar]
  10. Churi C.R. Shroff R. Wang Y. Rashid A. Kang H.C. Weatherly J. Zuo M. Zinner R. Hong D. Meric-Bernstam F. Janku F. Crane C.H. Mishra L. Vauthey J.N. Wolff R.A. Mills G. Javle M. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One 2014 9 12 115383 10.1371/journal.pone.0115383 25536104
    [Google Scholar]
  11. Neumann O. Lehmann U. Bartels S. Pfarr N. Albrecht T. Ilm K. Christmann J. Volckmar A.L. Goldschmid H. Kirchner M. Allgäuer M. Walker M. Kreipe H. Tannapfel A. Weichert W. Schirmacher P. Kazdal D. Stenzinger A. First proficiency testing for NGS ‐based and combined NGS ‐ and FISH ‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma. J. Pathol. Clin. Res. 2023 9 2 100 107 10.1002/cjp2.308 36635225
    [Google Scholar]
  12. Madoff D.C. Abi-Jaoudeh N. Braxton D. Goyal L. Jain D. Odisio B.C. An expert, multidisciplinary perspective on best practices in biomarker testing in intrahepatic cholangiocarcinoma. Oncologist 2022 27 10 884 891 10.1093/oncolo/oyac139
    [Google Scholar]
  13. Lamarca A. Kapacee Z. Breeze M. Bell C. Belcher D. Staiger H. Taylor C. McNamara M.G. Hubner R.A. Valle J.W. Molecular profiling in daily clinical practice: Practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J. Clin. Med. 2020 9 9 2854 10.3390/jcm9092854 32899345
    [Google Scholar]
  14. Lamarca A. Frizziero M. McNamara M.G. Valle J.W. Clinical and translational research challenges in biliary tract cancers. Curr. Med. Chem. 2020 27 29 4756 4777 10.2174/0929867327666200123090153 31971102
    [Google Scholar]
  15. Guedj N. Pathology of cholangiocarcinomas. Curr. Oncol. 2022 30 1 370 380 10.3390/curroncol30010030 36661679
    [Google Scholar]
  16. Kendall T. Verheij J. Gaudio E. Evert M. Guido M. Goeppert B. Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019 39 S1 7 18 10.1111/liv.14093 30882996
    [Google Scholar]
  17. Cho M. Ahn S. Hong M. Bang H. Van Vrancken M. Kim S. Lee J. Park S.H. Park J.O. Park Y.S. Lim H.Y. Kang W.K. Sun J.M. Lee S.H. Ahn M.J. Park K. Kim D.H. Lee S. Park W. Kim K.M. Tissue recommendations for precision cancer therapy using next generation sequencing: A comprehensive single cancer center’s experiences. Oncotarget 2017 8 26 42478 42486 10.18632/oncotarget.17199 28477007
    [Google Scholar]
  18. Lamarca A. Morfouace M. Tejpar S. Oliveira J. Capela A. Penel N. Gennigens C. Brasiuniene B. Peron J. Stevovic A. Blay J.Y. Klümpen H.J. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): Too few patients with matched treatment in Europe. Ann. Oncol. 2022 33 11 1200 1202 10.1016/j.annonc.2022.07.006 35926814
    [Google Scholar]
  19. Poudel B.H. Koks S. The whole transcriptome analysis using FFPE and fresh tissue samples identifies the molecular fingerprint of osteosarcoma. Exp. Biol. Med. 2024 249 10161 10.3389/ebm.2024.10161 38966281
    [Google Scholar]
  20. Li J.S. Han T.J. Jing N. Li L. Zhang X.H. Ma F.Z. Liu J.Y. Obesity and the risk of cholangiocarcinoma: A meta-analysis. Tumour Biol. 2014 35 7 6831 6838 10.1007/s13277‑014‑1939‑4 24729126
    [Google Scholar]
  21. Cho M.T. Gholami S. Gui D. Tejaswi S.L. Fananapazir G. Abi-Jaoudeh N. Jutric Z. Samarasena J.B. Li X. Valerin J.B. Mercer J. Dayyani F. Optimizing the diagnosis and biomarker testing for patients with intrahepatic cholangiocarcinoma: A multidisciplinary approach. Cancers 2022 14 2 392 10.3390/cancers14020392 35053557
    [Google Scholar]
  22. Gan Q. Roy-Chowdhuri S. Small but powerful: The promising role of small specimens for biomarker testing. J. Am. Soc. Cytopathol. 2020 9 5 450 460 10.1016/j.jasc.2020.05.001 32507626
    [Google Scholar]
  23. Gonzalez-Aguirre A. Covey A.M. Brown K.T. Brody L.A. Boas F.E. Sofocleous C.T. Maybody M. Getrajdman G.I. Erinjeri J.P. Comparison of biliary brush biopsy and fine needle biopsy in the diagnosis of biliary strictures. Minim. Invasive Ther. Allied Technol. 2018 27 5 278 283 10.1080/13645706.2018.1427597 29390936
    [Google Scholar]
  24. Ogawa T. Ito K. Koshita S. Kanno Y. Masu K. Kusunose H. Sakai T. Murabayashi T. Hasegawa S. Noda Y. Usefulness of cholangioscopic-guided mapping biopsy using SpyGlass DS for preoperative evaluation of extrahepatic cholangiocarcinoma: A pilot study. Endosc. Int. Open 2018 6 2 E199 E204 10.1055/s‑0043‑117949 29399618
    [Google Scholar]
  25. Kamp E.J.C.A. Dinjens W.N.M. Doukas M. Bruno M.J. de Jonge P.J.F. Peppelenbosch M.P. de Vries A.C. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap. Adv. Gastroenterol. 2021 14 17562848211002023 10.1177/17562848211002023 33948111
    [Google Scholar]
  26. Rodrigues P.M. Vogel A. Arrese M. Balderramo D.C. Valle J.W. Banales J.M. Next- generation biomarkers for cholangiocarcinoma. Cancers 2021 13 13 3222 10.3390/cancers13133222 34203269
    [Google Scholar]
  27. Singhi A.D. Nikiforova M.N. Chennat J. Papachristou G.I. Khalid A. Rabinovitz M. Das R. Sarkaria S. Ayasso M.S. Wald A.I. Monaco S.E. Nalesnik M. Ohori N.P. Geller D. Tsung A. Zureikat A.H. Zeh H. Marsh J.W. Hogg M. Lee K. Bartlett D.L. Pingpank J.F. Humar A. Bahary N. Dasyam A.K. Brand R. Fasanella K.E. McGrath K. Slivka A. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut 2020 69 1 52 61 10.1136/gutjnl‑2018‑317817 30971436
    [Google Scholar]
  28. Morris S. Subramanian J. Gel E. Runger G. Thompson E. Mallery D. Weiss G. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS One 2018 13 4 0196556 10.1371/journal.pone.0196556 29702695
    [Google Scholar]
  29. Corless C.L. Next-generation sequencing in cancer diagnostics. J. Mol. Diagn. 2016 18 6 813 816 10.1016/j.jmoldx.2016.08.002 27664753
    [Google Scholar]
  30. Smits A.J.J. Kummer J.A. de Bruin P.C. Bol M. van den Tweel J.G. Seldenrijk K.A. Willems S.M. Offerhaus G.J.A. de Weger R.A. van Diest P.J. Vink A. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod. Pathol. 2014 27 2 168 174 10.1038/modpathol.2013.134 23887293
    [Google Scholar]
  31. Geiersbach K. Adey N. Welker N. Elsberry D. Malmberg E. Edwards S. Downs-Kelly E. Salama M. Bronner M. Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors. Cancer Genet. 2016 209 1-2 42 49 10.1016/j.cancergen.2015.12.004 26767919
    [Google Scholar]
  32. Mathieson W. Thomas G.A. Why formalin-fixed, paraffin-embedded biospecimens must be used in genomic medicine: An evidence-based review and conclusion. J. Histochem. Cytochem. 2020 68 8 543 552 10.1369/0022155420945050 32697619
    [Google Scholar]
  33. Cappello F. Angerilli V. Munari G. Ceccon C. Sabbadin M. Pagni F. Fusco N. Malapelle U. Fassan M. FFPE- based NGS approaches into clinical practice: The limits of glory from a pathologist viewpoint. J. Pers. Med. 2022 12 5 750 10.3390/jpm12050750 35629172
    [Google Scholar]
  34. Do H. Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: Causes and strategies for minimization. Clin. Chem. 2015 61 1 64 71 10.1373/clinchem.2014.223040 25421801
    [Google Scholar]
  35. Greytak S.R. Engel K.B. Zmuda E. Casas-Silva E. Guan P. Hoadley K.A. Mungall A.J. Wheeler D.A. Doddapaneni H.V. Moore H.M. National cancer institute biospecimen evidence-based practices: Harmonizing procedures for nucleic acid extraction from formalin-fixed, paraffin-embedded tissue. Biopreserv. Biobank. 2018 16 4 247 250 10.1089/bio.2018.0046 29920119
    [Google Scholar]
  36. Voss J.S. Holtegaard L.M. Kerr S.E. Fritcher E.G.B. Roberts L.R. Gores G.J. Zhang J. Highsmith W.E. Halling K.C. Kipp B.R. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum. Pathol. 2013 44 7 1216 1222 10.1016/j.humpath.2012.11.006 23391413
    [Google Scholar]
  37. Shiau C.J. Babwah J.P. da Cunha Santos G. Sykes J.R. Boerner S.L. Geddie W.R. Leighl N.B. Wei C. Kamel-Reid S. Hwang D.M. Tsao M.S. Sample features associated with success rates in population-based EGFR mutation testing. J. Thorac. Oncol. 2014 9 7 947 956 10.1097/JTO.0000000000000196 24922009
    [Google Scholar]
  38. Kim B. Cho N.Y. Shin S.H. Kwon H.J. Jang J.J. Kang G.H. CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma. Virchows Arch. 2009 455 4 343 351 10.1007/s00428‑009‑0829‑4 19763613
    [Google Scholar]
  39. Schöniger S. Rüschoff J. Mismatch repair deficiency and microsatellite instability. Encyclopedia 2022 2 3 1559 1576 10.3390/encyclopedia2030106
    [Google Scholar]
  40. Ho X.D. Phung P. Le Q. V.; H Nguyen, V.; Reimann, E.; Prans, E.; Kõks, G.; Maasalu, K.; Le, N.T.N.; H Trinh, L.; G Nguyen, H.; Märtson, A.; Kõks, S. Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples. Exp. Biol. Med. 2017 242 18 1802 1811 10.1177/1535370217736512 29050494
    [Google Scholar]
  41. a Reimann E. Kõks S. Ho X.D. Maasalu K. Märtson A. Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum. Genomics 2014 8 1 20 25496518
    [Google Scholar]
  42. b PMID: 25496518 Lin C. Liu X. Zheng B. Ke R. Tzeng C.M. Liquid biopsy, ctDNA diagnosis through NGS. Life 2021 11 9 890 10.3390/life11090890 34575039
    [Google Scholar]
  43. Han J.Y. Ahn K.S. Kim T.S. Kim Y.H. Cho K.B. Shin D.W. Baek W.K. Suh S.I. Jang B.C. Kang K.J. Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer. Cancers 2021 13 18 4581 10.3390/cancers13184581 34572808
    [Google Scholar]
  44. Driescher C. Fuchs K. Haeberle L. Goering W. Frohn L. Opitz F.V. Haeussinger D. Knoefel W.T. Keitel V. Esposito I. Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer. Cancers 2020 13 1 39 10.3390/cancers13010039 33375555
    [Google Scholar]
  45. Gou Q. Zhang C.Z. Sun Z.H. Wu L.G. Chen Y. Mo Z.Q. Mai Q.C. He J. Zhou Z.X. Shi F. Cui W. Zou W. Lv L. Zhuang W.H. Xu R.D. Li W.K. Zhang J. Du H.W. Xiang J.X. Wang H.Z. Hou T. Li S.T. Li Y. Chen X.M. Zhou Z.J. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open 2021 6 6 100275 10.1016/j.esmoop.2021.100275 34653800
    [Google Scholar]
  46. Pascual J. Attard G. Bidard F.C. Curigliano G. De Mattos-Arruda L. Diehn M. Italiano A. Lindberg J. Merker J.D. Montagut C. Normanno N. Pantel K. Pentheroudakis G. Popat S. Reis-Filho J.S. Tie J. Seoane J. Tarazona N. Yoshino T. Turner N.C. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2022 33 8 750 768 10.1016/j.annonc.2022.05.520 35809752
    [Google Scholar]
  47. Shotton R. Lamarca A. Valle J. McNamara M.G. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. World J. Gastrointest. Oncol. 2021 13 9 1073 1085 10.4251/wjgo.v13.i9.1073
    [Google Scholar]
  48. Goyal L. Saha S.K. Liu L.Y. Siravegna G. Leshchiner I. Ahronian L.G. Lennerz J.K. Vu P. Deshpande V. Kambadakone A. Mussolin B. Reyes S. Henderson L. Sun J.E. Van Seventer E.E. Gurski J.M. Baltschukat S. Schacher-Engstler B. Barys L. Stamm C. Furet P. Ryan D.P. Stone J.R. Iafrate A.J. Getz G. Porta D.G. Tiedt R. Bardelli A. Juric D. Corcoran R.B. Bardeesy N. Zhu A.X. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017 7 3 252 263 10.1158/2159‑8290.CD‑16‑1000 28034880
    [Google Scholar]
  49. Khan S. Lohani A. Tiwari P. Kadiri S.K. Exploring Betula alnoides bark: Insilico and preclinical insights into its antioxidant and lipid-lowering effects in hypercholesterolemia. Obes. Med. 2025 54 100583 10.1016/j.obmed.2025.100583
    [Google Scholar]
  50. Goyal L. Shi L. Liu L.Y. Fece de la Cruz F. Lennerz J.K. Raghavan S. Leschiner I. Elagina L. Siravegna G. Ng R.W.S. Vu P. Patra K.C. Saha S.K. Uppot R.N. Arellano R. Reyes S. Sagara T. Otsuki S. Nadres B. Shahzade H.A. Dey-Guha I. Fetter I.J. Baiev I. Van Seventer E.E. Murphy J.E. Ferrone C.R. Tanabe K.K. Deshpande V. Harding J.J. Yaeger R. Kelley R.K. Bardelli A. Iafrate A.J. Hahn W.C. Benes C.H. Ting D.T. Hirai H. Getz G. Juric D. Zhu A.X. Corcoran R.B. Bardeesy N. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019 9 8 1064 1079 10.1158/2159‑8290.CD‑19‑0182 31109923
    [Google Scholar]
  51. Mouliere F. Chandrananda D Piskorz AM Moore EK Morris J Ahlborn LB Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 2018 10 466 eaat4921 10.1126/scitranslmed.aat4921
    [Google Scholar]
  52. Pirosa M.C. Borchmann S. Jardin F. Gaidano G. Rossi D. Controversies in the interpretation of liquid biopsy data in lymphoma. HemaSphere 2022 6 6 727 10.1097/HS9.0000000000000727 35747846
    [Google Scholar]
  53. Zhao X. Dai F. Mei L. Huang D. Shen X. Zhang H. She X. Ma Z. The potential use of dynamics changes of ctDNA and cfDNA in the perioperative period to predict the recurrence risk in early NSCLC. Front. Oncol. 2021 11 671963 10.3389/fonc.2021.671963 34336662
    [Google Scholar]
  54. Husain H. Pavlick D.C. Fendler B.J. Madison R.W. Decker B. Gjoerup O. Parachoniak C.A. McLaughlin-Drubin M. Erlich R.L. Schrock A.B. Frampton G.M. Das Thakur M. Oxnard G.R. Tukachinsky H. Tumor fraction correlates with detection of actionable variants across 23,000 circulating tumor DNA samples. JCO Precis. Oncol. 2022 6 6 2200261 10.1200/PO.22.00261 36265119
    [Google Scholar]
  55. Welland S. deCastro T. Bathon M. Wirth T.C. Reineke-Plaaß T. Saborowski M. Lehmann U. Saborowski A. Vogel A. Molecular diagnostics and therapies for gastrointestinal tumors: A real-world experience. J. Cancer Res. Clin. Oncol. 2022 148 8 2137 2144 10.1007/s00432‑021‑03774‑5 34436668
    [Google Scholar]
  56. Pasquale R. Forgione L. Roma C. Fenizia F. Bergantino F. Rachiglio A.M. De Luca A. Gallo M. Maiello M.R. Palumbo G. Morabito A. Azzaro R. Normanno N. Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: Clinical and biological implications. Transl. Lung Cancer Res. 2020 9 1 61 70 10.21037/tlcr.2020.01.01 32206554
    [Google Scholar]
  57. Rachiglio A.M. Abate R.E. Sacco A. Pasquale R. Fenizia F. Lambiase M. Morabito A. Montanino A. Rocco G. Romano C. Nappi A. Iaffaioli R.V. Tatangelo F. Botti G. Ciardiello F. Maiello M.R. De Luca A. Normanno N. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016 7 41 66595 66605 10.18632/oncotarget.10704 27448974
    [Google Scholar]
  58. Goyal L. Meric-Bernstam F. Hollebecque A. Valle J.W. Morizane C. Karasic T.B. Abrams T.A. Furuse J. Kelley R.K. Cassier P.A. Klümpen H.J. Chang H.M. Chen L.T. Tabernero J. Oh D.Y. Mahipal A. Moehler M. Mitchell E.P. Komatsu Y. Masuda K. Ahn D. Epstein R.S. Halim A.B. Fu Y. Salimi T. Wacheck V. He Y. Liu M. Benhadji K.A. Bridgewater J.A. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 2023 388 3 228 239 10.1056/NEJMoa2206834 36652354
    [Google Scholar]
  59. Arrichiello G. Nacca V. Paragliola F. Giunta E.F. Liquid biopsy in biliary tract cancer from blood and bile samples: Current knowledge and future perspectives. Explor. Target. Antitumor Ther. 2022 3 3 362 374 10.37349/etat.2022.00087 36045913
    [Google Scholar]
  60. Ondracek R.P. Chen J. Marosy B. Szewczyk S. Medico L. Mohan A.S. Nair P. Pratt R. Roh J.M. Khoury T. Carpten J. Kushi L.H. Palmer J.R. Doheny K. Davis W. Higgins M.J. Yao S. Ambrosone C.B. Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large Cancer epidemiologic study. BMC Genomics 2022 23 1 614 10.1186/s12864‑022‑08837‑6 36008758
    [Google Scholar]
  61. Cao J. Hu J. Liu S. Meric-Bernstam F. Abdel-Wahab R. Xu J. Li Q. Yan M. Feng Y. Lin J. Zhao S. Wang J. Kwong L.N. Hu J. Carapeto F. Borad M.J. Wang K. Javle M. Zhao H. Intrahepatic cholangiocarcinoma: Genomic heterogeneity between eastern and western patients. JCO Precis. Oncol. 2020 4 4 557 569 10.1200/PO.18.00414 32923885
    [Google Scholar]
  62. Goeppert B. Toth R. Singer S. Albrecht T. Lipka D.B. Lutsik P. Brocks D. Baehr M. Muecke O. Assenov Y. Gu L. Endris V. Stenzinger A. Mehrabi A. Schirmacher P. Plass C. Weichenhan D. Roessler S. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology 2019 69 5 2091 2106 10.1002/hep.30493 30615206
    [Google Scholar]
  63. Peng Y. Meng G. Sheng X. Gao H. Transcriptome and DNA methylation analysis reveals molecular mechanisms underlying intrahepatic cholangiocarcinoma progression. J. Cell. Mol. Med. 2021 25 13 6373 6387 10.1111/jcmm.16615 34013637
    [Google Scholar]
  64. He K. Feng Y. An S. Liu F. Xiang G. Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatic cholangiocarcinoma. Genomics 2022 114 1 241 252 10.1016/j.ygeno.2021.12.008 34942351
    [Google Scholar]
  65. Dragomir M.P. Calina T.G. Perez E. Schallenberg S. Chen M. Albrecht T. Koch I. Wolkenstein P. Goeppert B. Roessler S. Calin G.A. Sers C. Horst D. Roßner F. Capper D. DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumours. EBioMedicine 2023 93 104657 10.1016/j.ebiom.2023.104657 37348162
    [Google Scholar]
  66. Job S. Rapoud D. Dos Santos A. Gonzalez P. Desterke C. Pascal G. Elarouci N. Ayadi M. Adam R. Azoulay D. Castaing D. Vibert E. Cherqui D. Samuel D. Sa Cuhna A. Marchio A. Pineau P. Guettier C. de Reyniès A. Faivre J. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020 72 3 965 981 10.1002/hep.31092 31875970
    [Google Scholar]
  67. Chen X. Dong L. Chen L. Wang Y. Du J. Ma L. Yan X. Huang J. Liao M. Chen X. Liu D. Li J. Zhang B. Teng W. Yuan K. Sun D. Gao Q. Zeng Y. Epigenome-wide development and validation of a prognostic methylation score in intrahepatic cholangiocarcinoma based on machine learning strategies. Hepatobiliary Surg. Nutr. 2023 12 4 478 494 10.21037/hbsn‑21‑424 37601000
    [Google Scholar]
  68. Liao H. Chen X. Wang H. Lin Y. Chen L. Yuan K. Liao M. Jiang H. Peng J. Wu Z. Huang J. Li J. Zeng Y. Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers. Cancer Res. 2024 84 11 1747 1763 10.1158/0008‑5472.CAN‑23‑3298 38471085
    [Google Scholar]
  69. Ahn K.S. O’Brien D. Kang Y.N. Mounajjed T. Kim Y.H. Kim T.S. Kocher J.P.A. Allotey L.K. Borad M.J. Roberts L.R. Kang K.J. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach. Hepatol. Int. 2019 13 4 490 500 10.1007/s12072‑019‑09954‑3 31214875
    [Google Scholar]
  70. Silvestri M. Nghia Vu T. Nichetti F. Niger M. Di Cosimo S. De Braud F. Pruneri G. Pawitan Y. Calza S. Cappelletti V. Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma. Cancer Med. 2023 12 8 10156 10168 10.1002/cam4.5719 36938752
    [Google Scholar]
  71. Chen Y. Liu D. Liu P. Chen Y. Yu H. Zhang Q. Identification of biomarkers of intrahepatic cholangiocarcinoma via integrated analysis of mRNA and miRNA microarray data. Mol. Med. Rep. 2017 15 3 1051 1056 10.3892/mmr.2017.6123 28098904
    [Google Scholar]
  72. Yang W. Li Y. Song X. Xu J. Xie J. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. Oncotarget 2017 8 16 26591 26599 10.18632/oncotarget.15721 28427159
    [Google Scholar]
  73. Peraldo-Neia C. Ostano P. Cavalloni G. Pignochino Y. Sangiolo D. De Cecco L. Marchesi E. Ribero D. Scarpa A. De Rose A.M. Giuliani A. Calise F. Raggi C. Invernizzi P. Aglietta M. Chiorino G. Leone F. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. BMC Genomics 2018 19 1 440 10.1186/s12864‑018‑4829‑0 29871612
    [Google Scholar]
  74. Cao J. Sun L. Li J. Zhou C. Cheng L. Chen K. Yan B. Qian W. Ma Q. Duan W. A novel three miRNA signature predicts survival in cholangiocarcinoma based on RNA Seq data. Oncol. Rep. 2018 40 3 1422 1434 10.3892/or.2018.6534 29956786
    [Google Scholar]
  75. Ye Z. Zeng Z. Wang D. Lei S. Shen Y. Chen Z. Identification of key genes associated with the progression of intrahepatic cholangiocarcinoma using weighted gene co expression network analysis. Oncol. Lett. 2020 20 1 483 494 10.3892/ol.2020.11600 32565973
    [Google Scholar]
  76. Xia L. Chen X. Yang J. Zhu S. Zhang L. Yin Q. Hong Y. Chen H. Chen G. Li H. Long non-coding RNA-PAICC promotes the tumorigenesis of human intrahepatic cholangiocarcinoma by increasing YAP1 transcription. Front. Oncol. 2021 10 595533 10.3389/fonc.2020.595533 33552968
    [Google Scholar]
  77. Li H. Qu L. Zhang H. Liu J. Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci. Rep. 2021 11 1 13713 10.1038/s41598‑021‑93250‑4 34211100
    [Google Scholar]
  78. Rhee H. Ko J.E. Chung T. Jee B.A. Kwon S.M. Nahm J.H. Seok J.Y. Yoo J.E. Choi J.S. Thorgeirsson S.S. Andersen J.B. Lee H.S. Woo H.G. Park Y.N. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int. 2018 38 1 113 124 10.1111/liv.13492 28608943
    [Google Scholar]
  79. Zhang M. Yang H. Wan L. Wang Z. Wang H. Ge C. Liu Y. Hao Y. Zhang D. Shi G. Gong Y. Ni Y. Wang C. Zhang Y. Xi J. Wang S. Shi L. Zhang L. Yue W. Pei X. Liu B. Yan X. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J. Hepatol. 2020 73 5 1118 1130 10.1016/j.jhep.2020.05.039 32505533
    [Google Scholar]
  80. Xiang X. Liu Z. Zhang C. Li Z. Gao J. Zhang C. Cao Q. Cheng J. Liu H. Chen D. Cheng Q. Zhang N. Xue R. Bai F. Zhu J. IDH mutation subgroup status associates with intratumor heterogeneity and the tumor microenvironment in intrahepatic cholangiocarcinoma. Adv. Sci. (Weinh.) 2021 8 17 2101230 10.1002/advs.202101230 34250753
    [Google Scholar]
  81. Zhou Q. Ji L. Shi X. Deng D. Guo F. Wang Z. Liu W. Zhang J. Xia S. Shang D. INTS8 is a therapeutic target for intrahepatic cholangiocarcinoma via the integration of bioinformatics analysis and experimental validation. Sci. Rep. 2021 11 1 23649 10.1038/s41598‑021‑03017‑0 34880328
    [Google Scholar]
  82. Liao W. Du J. Li L. Wu X. Chen X. Feng Q. Xu L. Chen X. Liao M. Huang J. Yuan K. Zeng Y. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma. J. Exp. Clin. Cancer Res. 2023 42 1 125 10.1186/s13046‑023‑02699‑w 37198696
    [Google Scholar]
  83. Zhang L.T. Yang Y.F. Chen X.M. Wang S.B. Tong G.L. IL23R as an indicator of immune infiltration and poor prognosis in intrahepatic cholangiocarcinoma: A bioinformatics analysis. Transl. Cancer Res. 2023 12 10 2461 2476 10.21037/tcr‑23‑455 37969393
    [Google Scholar]
  84. Correa-Gallego C. Maddalo D. Doussot A. Kemeny N. Kingham T.P. Allen P.J. D’Angelica M.I. DeMatteo R.P. Betel D. Klimstra D. Jarnagin W.R. Ventura A. Circulating plasma levels of MicroRNA-21 and MicroRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma. PLoS One 2016 11 9 0163699 10.1371/journal.pone.0163699 27685844
    [Google Scholar]
  85. Carpino G. Overi D. Melandro F. Grimaldi A. Cardinale V. Di Matteo S. Mennini G. Rossi M. Alvaro D. Barnaba V. Gaudio E. Mancone C. Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin. Proteomics 2019 16 1 37 10.1186/s12014‑019‑9257‑x 31687002
    [Google Scholar]
  86. Dos Santos A. Court M. Thiers V. Sar S. Guettier C. Samuel D. Bréchot C. Garin J. Demaugre F. Masselon C.D. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol. Cell. Proteomics 2010 9 9 1991 2004 10.1074/mcp.M110.000026 20513801
    [Google Scholar]
  87. Shen Y. Xu S. Ye C. Li Q. Chen R. Wu W. Jiang Q. Jia Y. Zhang X. Fan L. Fu W. Jiang M. Chen J. Timko M.P. Zhao P. Ruan J. Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma. iScience 2023 26 2 106003 10.1016/j.isci.2023.106003 36852159
    [Google Scholar]
  88. Yi X. Zhu J. Liu W. Peng L. Lu C. Sun P. Huang L. Nie X. Huang S. Guo T. Zhu Y. Proteome landscapes of human hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Mol. Cell. Proteomics 2023 22 8 100604 10.1016/j.mcpro.2023.100604 37353004
    [Google Scholar]
  89. Guo Y. Li Q. Ren W. Wu H. Wang C. Li X. Xue B. Qiu Y. Zhang J. Chen J. Fang L. Quantitative proteomics reveals down-regulated glycolysis/gluconeogenesis in the large-duct type intrahepatic cholangiocarcinoma. J. Proteome Res. 2022 21 10 2504 2514 10.1021/acs.jproteome.2c00472 36066509
    [Google Scholar]
  90. Polidoro M.A. Franceschini B. Milana F. Soldani C. Carriero R. Aghemo A. Donadon M. Torzilli G. Pastorelli R. Brunelli L. Lleo A. Decoding human intrahepatic cholangiocarcinoma metabolism: Unveiling the impact of SLC2A3 on aggressiveness and prognosis. Dig. Liver Dis. 2024 56 S6 S7 10.1016/j.dld.2024.01.010
    [Google Scholar]
  91. Cavalloni G. Peraldo-Neia C. Massa A. Bergamini C. Trentini A. De Rosa G. Daniele L. Ciccosanti F. Cervellati C. Leone F. Aglietta M. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. BMC Cancer 2021 21 1 865 10.1186/s12885‑021‑08576‑z 34320944
    [Google Scholar]
  92. Li J. Lu J. Lv S. Sun S. Liu C. Xu F. Sun H. Yang J. Wang X. Zhong X. Lu J. Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma. BMC Gastroenterol. 2022 22 1 269 10.1186/s12876‑022‑02354‑2 35637430
    [Google Scholar]
  93. Haznadar M. Diehl C.M. Parker A.L. Krausz K.W. Bowman E.D. Rabibhadana S. Forgues M. Bhudhisawasdi V. Gonzalez F.J. Mahidol C. Budhu A. Wang X.W. Ruchirawat M. Harris C.C. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma. Cancer Epidemiol. Biomarkers Prev. 2019 28 10 1704 1711 10.1158/1055‑9965.EPI‑19‑0453 31358519
    [Google Scholar]
  94. Yang X. Lian B. Zhang N. Long J. Li Y. Xue J. Chen X. Wang Y. Wang Y. Xun Z. Piao M. Zhu C. Wang S. Sun H. Song Z. Lu L. Dong X. Wang A. Liu W. Pan J. Hou X. Guan M. Huo L. Shi J. Zhang H. Zhou J. Lu Z. Mao Y. Sang X. Wu L. Yang X. Wang K. Zhao H. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. BMC Med. 2024 22 1 42 10.1186/s12916‑024‑03257‑7 38281914
    [Google Scholar]
  95. Romanidou O. Kotoula V. Fountzilas G. Bridging cancer biology with the clinic: Comprehending and exploiting IDH gene mutations in gliomas. Cancer Genomics Proteomics 2018 15 5 421 436 10.21873/cgp.20101 30194083
    [Google Scholar]
  96. Wang P. Dong Q. Zhang C. Kuan P-F. Liu Y. Jeck W.R. Andersen J.B. Jiang W. Savich G.L. Tan T-X. Auman J.T. Hoskins J.M. Misher A.D. Moser C.D. Yourstone S.M. Kim J.W. Cibulskis K. Getz G. Hunt H.V. Thorgeirsson S.S. Roberts L.R. Ye D. Guan K-L. Xiong Y. Qin L-X. Chiang D.Y. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013 32 25 3091 3100 10.1038/onc.2012.315 22824796
    [Google Scholar]
  97. Grassian A.R. Pagliarini R. Chiang D.Y. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 2014 30 3 295 302 10.1097/MOG.0000000000000050 24569570
    [Google Scholar]
  98. Nakagawa M. Yamaguchi M. Endo M. Machida Y. Hattori A. Tanzawa F. Tsutsumi S. Kitabayashi I. Kawai A. Nakatani F. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. J. Bone Oncol. 2022 34 100430 10.1016/j.jbo.2022.100430 35493690
    [Google Scholar]
  99. Lu C. Ward P.S. Kapoor G.S. Rohle D. Turcan S. Abdel-Wahab O. Edwards C.R. Khanin R. Figueroa M.E. Melnick A. Wellen K.E. O’Rourke D.M. Berger S.L. Chan T.A. Levine R.L. Mellinghoff I.K. Thompson C.B. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483 7390 474 478 10.1038/nature10860 22343901
    [Google Scholar]
  100. Grassian A.R. Lin F. Barrett R. Liu Y. Jiang W. Korpal M. Astley H. Gitterman D. Henley T. Howes R. Levell J. Korn J.M. Pagliarini R. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J. Biol. Chem. 2012 287 50 42180 42194 10.1074/jbc.M112.417832 23038259
    [Google Scholar]
  101. Javle M. Bekaii-Saab T. Jain A. Wang Y. Kelley R.K. Wang K. Kang H.C. Catenacci D. Ali S. Krishnan S. Ahn D. Bocobo A.G. Zuo M. Kaseb A. Miller V. Stephens P.J. Meric-Bernstam F. Shroff R. Ross J. Biliary cancer: Utility of next‐generation sequencing for clinical management. Cancer 2016 122 24 3838 3847 10.1002/cncr.30254 27622582
    [Google Scholar]
  102. Mitelman F. Johansson B. Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007 7 4 233 245 10.1038/nrc2091 17361217
    [Google Scholar]
  103. Lamarca A. Barriuso J. McNamara M.G. Valle J.W. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J. Hepatol. 2020 73 1 170 185 10.1016/j.jhep.2020.03.007 32171892
    [Google Scholar]
  104. Graham R.P. Barr Fritcher E.G. Pestova E. Schulz J. Sitailo L.A. Vasmatzis G. Murphy S.J. McWilliams R.R. Hart S.N. Halling K.C. Roberts L.R. Gores G.J. Couch F.J. Zhang L. Borad M.J. Kipp B.R. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 2014 45 8 1630 1638 10.1016/j.humpath.2014.03.014 24837095
    [Google Scholar]
  105. Zhou P.Y. Zhou C. Gan W. Tang Z. Sun B.Y. Huang J.L. Liu G. Liu W.R. Tian M.X. Jiang X.F. Wang H. Tao C.Y. Fang Y. Qu W.F. Huang R. Zhu G.Q. Huang C. Fu X.T. Ding Z.B. Gao Q. Zhou J. Shi Y.H. Yi Y. Fan J. Qiu S.J. Single-cell and spatial architecture of primary liver cancer. Commun. Biol. 2023 6 1 1181 10.1038/s42003‑023‑05455‑0 37985711
    [Google Scholar]
  106. Sigismund S. Avanzato D. Lanzetti L. Emerging functions of the EGFR in cancer. Mol. Oncol. 2018 12 1 3 20 10.1002/1878‑0261.12155 29124875
    [Google Scholar]
  107. Sirica A.E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 2008 14 46 7033 7058 10.3748/wjg.14.7033 19084911
    [Google Scholar]
  108. Endo K. Yoon B.I.L. Pairojkul C. Demetris A.J. Sirica A.E. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002 36 2 439 450 10.1053/jhep.2002.34435 12143054
    [Google Scholar]
  109. Ma D. Wei P. Liu H. Hao J. Chen Z. Chu Y. Li Z. Shi W. Yuan Z. Cheng Q. Gao J. Zhu J. Li Z. Multi-omics-driven discovery of invasive patterns and treatment strategies in CA19-9 positive intrahepatic cholangiocarcinoma. J. Transl. Med. 2024 22 1 1031 10.1186/s12967‑024‑05854‑9 39548460
    [Google Scholar]
  110. Czauderna C. Kirstein M.M. Tews H.C. Vogel A. Marquardt J.U. Molecular subtypes and precision oncology in intrahepatic cholangiocarcinoma. J. Clin. Med. 2021 10 13 2803 10.3390/jcm10132803 34202401
    [Google Scholar]
/content/journals/cg/10.2174/0113892029392506251115053421
Loading
Genetic Uncertainties Fueling Cholangiocarcinoma Progression
Bentham Science Publishers ; https://doi.org/10.2174/0113892029392506251115053421
/content/journals/cg/10.2174/0113892029392506251115053421
/content/journals/cg/10.2174/0113892029392506251115053421
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Intrahepatic cholangiocarcinoma ; treatment strategies ; genomic research ; epigenetic alterations ; malignant transformation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test